FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Wang Theodore T 2. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [ EKSO ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O EKSO BIONICS HOLDINGS, INC., 1414 HARBOUR WAY SOUTH, SUITE 1201
3. Date of Earliest Transaction (MM/DD/YYYY)
7/23/2020
(Street)
RICHMOND, CA 94804
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  7/23/2020    A    7383  A $0.00 (1) 9958 (2) D   
Common Stock                 774400 (2) I (3) By Puissance Cross-Border Opportunities II LLC 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The grant consists of RSUs that fully vest one year from the date of grant, or July 23, 2021.
(2)  After taking into account the 1-for-15 reverse stock split effective March 24, 2020.
(3)  These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Wang Theodore T
C/O EKSO BIONICS HOLDINGS, INC.
1414 HARBOUR WAY SOUTH, SUITE 1201
RICHMOND, CA 94804
X X

Puissance Cross-Border Opportunities II LLC
C/O PUISSANCE CAPITAL FUND (GP) LLC
950 THIRD AVENUE, 25TH FLOOR
NEW YORK, NY 

X

Puissance Capital Fund (GP) LLC
950 THIRD AVENUE, 25TH FLOOR
NEW YORK, NY 10022

X

Puissance Capital Management LP
950 THIRD AVENUE, 25TH FLOOR
NEW YORK, NY 10022

X

Puissance Capital Management (GP) LLC
950 THIRD AVENUE, 25TH FLOOR
NEW YORK, NY 10022

X


Signatures
/s/ Theodore T. Wang 7/27/2020
**Signature of Reporting Person Date
Puissance Cross-Border Opportunities II LLC, By: Puissance Capital Fund (GP) LLC, its general partner, By: Theodore T. Wang, Managing Member 7/27/2020
**Signature of Reporting Person Date
Puissance Capital Fund (GP) LLC, By: Theodore T. Wang, Managing Member 7/27/2020
**Signature of Reporting Person Date
Puissance Capital Management LP, By: Puissance Capital Management (GP) LLC, its general partner, By: Theodore T. Wang, Managing Member 7/27/2020
**Signature of Reporting Person Date
Puissance Capital Management (GP) LLC, By: Theodore Wang, Managing Member 7/27/2020
**Signature of Reporting Person Date
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Ekso Bionics Charts.
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Ekso Bionics Charts.